Gsk Share Discussion Threads

[tradermichael] 28/7/2016 11:32

Its going up - the market likes it. Difficult to see any macroeconomic event that would reverse the impact that the weak pound (in instant response to the Brexit result) has produced in the same time frame. Therefore, looks like a strong hold for a long time ....... ;0).

[toffeeman] 27/7/2016 16:35

It went up (a little bit)

[tradermichael] 27/7/2016 14:08

Outperforming with these results - plus, this will push it up for a long time to come:

R&D pipeline development continues in core therapy
areas:
- EU approval received for Strimvelis first gene-therapy
for ADA-SCID
- Four significant filings expected in H2 2016:
Closed Triple for COPD, Shingrix vaccine for
shingles; Benlysta subcutaneous for lupus; sirukumab
for RA
- Novel anti-IL33R monoclonal antibody for severe
asthma licensed from Janssen
- First in class ICOS agonist antibody in Oncology
enters clinical development

[salpara111] 27/7/2016 13:49

yeah, I guess there would be an additional bump due to a further weakening of the £/$ exchange rate.

[ibug] 27/7/2016 13:40

If there is a rate cut on August 4th then this stock will keep stepping up the share price to about 1800p - 1900p...imo

[badtime] 27/7/2016 13:19

Happy days

[salpara111] 27/7/2016 13:18

overall pretty positive.
The question is....after such a strong run up over the last few weeks can it put some more on?
I have set a sell order for 1770 so will see if it gets executed in the next week or so.

[zzaxx99] 27/7/2016 12:04

GlaxoSmithKline PLC Half-year Report
27/07/2016 11:01am
UK Regulatory (RNS & others)

TIDMGSK

RNS Number : 4008F

GlaxoSmithKline PLC

27 July 2016


Issued: Wednesday, 27 July 2016, London U.K.
Results Announcement for the second quarter 2016 and Half-yearly Financial Report for the
half-year 2016

GSK delivers further progress against strategy with strong Q2 performance


Core results
Q2 2016 Growth H1 2016 Growth
------------ ------------
GBPm CER% GBP% GBPm CER% GBP%
-------- ----- ----- -------- ----- -----

Turnover 6,532 4 11 12,761 6 11
Core operating
profit 1,831 15 36 3,390 14 28
Core earnings
per share 24.5p 16 42 44.3p 12 28



Total results
Q2 2016 Growth H1 2016 Growth
---------------- ----------------
GBPm CER% GBP% GBPm CER% GBP%
-------- ------- ------- -------- ------- -------

Turnover 6,532 4 11 12,761 6 11
Operating (loss)/profit (151) >(100) >(100) 572 (98) (94)
Loss per share (9.0)p >(100) >(100) (3.2)p >(100) >(100)



Summary

-- Group sales GBP6.5 billion, +4% CER, with growth
across all three businesses
- Pharmaceuticals GBP3.9 billion, +2%; Vaccines
GBP960 million, +11%; Consumer Healthcare, GBP1.7
billion, +7%

-- New product sales GBP1.05 billion (Q2 2015, GBP446
million; Q1 2016, GBP821 million) driven by HIV
(Tivicay, Triumeq), Respiratory (Relvar/Breo,
Anoro, Incruse, Nucala) and Meningitis vaccines
(Bexsero, Menveo)
- New Pharmaceutical product sales represent 23%
of total Pharmaceutical sales (Q2 2015: 11%)
- Sales growth of new respiratory products more
than offset decline in sales of Seretide/Advair

-- New product sales and transaction & restructuring
benefits drive improved operating leverage and
margin delivery across all three businesses
- Incremental cost savings of GBP0.3 billion in
Q2 2016, with total annual cost savings now
at GBP2.3 billion against end 2017 target of
GBP3 billion
- Q2 core operating margins: Pharmaceuticals 35%,
Vaccines 28%, Consumer Healthcare 14%

-- Q2 core earnings per share 24.5p, +16% CER

-- Q2 total loss per share reflects impact of significant
Sterling currency adjustment to valuations of
liabilities associated with Consumer Healthcare
and HIV businesses
- Sterling forecasts for sales and cash flows
increased for majority-owned Consumer Healthcare
and HIV businesses
- Sterling forecasts for liabilities attributable
to minority interests therefore also increased,
resulting in charges of GBP1.8 billion in Q2
2016

-- 2016 core EPS percentage growth now expected
to be 11-12% CER
- If FX rates held at Q2 period end rates estimated
impact of +19% on 2016 Sterling core EPS growth

-- Q2 Net cash inflow from operations of GBP1.2
billion (Q2 2015: GBP0.2 billion)

-- 19p dividend declared for Q2. Continue to expect
80p for FY 2016 and 2017

-- R&D pipeline development continues in core therapy
areas:
- EU approval received for Strimvelis first gene-therapy
for ADA-SCID
- Four significant filings expected in H2 2016:
Closed Triple for COPD, Shingrix vaccine for
shingles; Benlysta subcutaneous for lupus; sirukumab
for RA
- Novel anti-IL33R monoclonal antibody for severe
asthma licensed from Janssen
- First in class ICOS agonist antibody in Oncology
enters clinical development

[tradermichael] 27/7/2016 08:09

GlaxoSmithKline plans 275 million pounds ($361 million) of new investments at three drug manufacturing sites in Britain, signaling its confidence in the country despite last month's vote to leave the European Union.


Britain's biggest drugmaker, which had argued against Brexit before the referendum, believes the UK remains an attractive place for making medicines, thanks to a skilled workforce and relatively low tax rates.

The country's so-called patent box boosts profits from patented innovations by halving the rate of corporation tax. This tax relief, which favors pharmaceutical companies, has come under fire in recent days from the opposition Labour Party.

GSK said on Wednesday it was investing in sites at Barnard Castle, in the north of England, Montrose, in Scotland, and Ware, north of London. It plans to increase production of next-generation respiratory drugs and biotech medicines.

The vast majority of these products will be exported.

"It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here," said Chief Executive Andrew Witty.

[solomon] 26/7/2016 19:34

If I were a chartist I would remark that there has been a penant formation atop a £2 flagpole (quite cheap for a flagpole). There is a possible £2 in the offing should the formation come to fruition. I only believe in charts once they have happened though. :-)

[tim 3] 26/7/2016 13:54

Thanks TraderMichael.

[alphorn] 26/7/2016 12:20

My back of the envelope would put the 56% higher. A great forex hedge. Will the market focus on the CER numbers???

[tradermichael] 26/7/2016 12:10

I calculated that since Brexit, 56% of the rise was directly on the weakness of the £, and the other 44% from underlying momentum not only on the basis of the continuing positive impact of stronger $ exchange rate, but coupled by the stronger growth of the company driven by new products, given that for a long time now, the stock has been oversold.

[tim 3] 26/7/2016 11:36

How much do people think the recent rise is down to sterlings weakness rather than the company itself ?

[tradermichael] 26/7/2016 10:51

If the market has already factored in some good results, I would expect a stable price, but the figures (including the $ exchange) might be so good that a surprise could result in a significant price jump ..... ;0)

[toffeeman] 26/7/2016 10:38

Yep - the price will either go up, go down or stay the same :)

[tradermichael] 26/7/2016 09:56

Q2 results out tomorrow .... I expect them to be very good .... possibly the market does as well. Anyone have a view to impact on price?

[tim 3] 25/7/2016 22:32

vs dollar/sterling since brexit.

[red5] 25/7/2016 22:15

so what she would be looking for a price target for the end of the year?

[tradermichael] 22/7/2016 08:34

GSK expects to supply up to 40 million doses across both vaccines for the US market in the 2016-17 season. One hundred percent of GSK supply is quadrivalent doses.

[stevemarkus] 20/7/2016 09:54

Reinvestment of dividends at a guess.

[stevenrevell] 20/7/2016 09:43

What's all the director share holdings about

[tradermichael] 18/7/2016 07:56

BEIJING--China's Food and Drug Administration approved GlaxoSmithKline PLC's (GSK) Cervarix, the first vaccine against human papilloma virus to be licensed for use in China for the prevention of cervical cancer.

The approval is expected to boost the sales of the U.K.-based drug company in China after its business there was severely hit by a bribery scandal three years ago.

Glaxo said Cervarix was tested on 6,000 subjects for a span of six years in China. It is registered in China for use in girls and women between nine and 25 years old. The commercial launch of Cervarix is expected in early 2017.

[garycook] 17/7/2016 04:06

£20 was going through my mind,and Bingo up pops Jeffries upgrade,and a 4% yield,is correct,and still about the FTSE 100 average.Predicted 1650,and now £20 also now.